Since then, a variety of driver gene mutations were gradually identified in NSCLC, such as EML4-ALK translocations and KRAS mutations (9), which has dramatically changed the treatment strategy of lung cancer. The gene discussed is EML4; the disease is non-small cell lung carcinoma.